iTeos Therapeutics, Inc.
ITOSDelisted Aug 29, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001808865
iTeos Therapeutics, Inc. was delisted on Aug 29, 2025; its insiders filed their last Form 4 on Aug 29, 2025; 137 institutions reported holding it in 13F filings for Q2 2025, worth $377.0M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 137
- Q2 2025, +5 vs. previous quarter
- 13F value
- $377.0M
- Reported value at the end of Q2 2025
- Superinvestors holding
- 0
- At the end of Q2 2025
Superinvestors holding ITOS, Q2 2025
No superinvestor reported holding ITOS at the end of Q2 2025.
Latest insider trades
Open-market purchases and sales by iTeos Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 11, 2025 (view filing) | Jun 9-10 | 2 days | Detheux MichelChief Executive Officer | SSale | −16.8K | $10.03 | −$168.4K | −11.0%135.9K after | 2 lots10b5-1 |
| Jun 11, 2025 (view filing) | Jun 9-10 | 2 days | Detheux MichelChief Executive Officer | SSale | −87.8K | $10.02 | −$879.8K | −100.0%0 after | 2 lots10b5-1 |
| Jun 6, 2025 (view filing) | Jun 4-6 | 2 days | Detheux MichelChief Executive Officer | SSale | −25.2K | $10.15 | −$255.9K | −15.6%135.9K after | 3 lots10b5-1 |
| Jun 6, 2025 (view filing) | Jun 4-6 | 2 days | Detheux MichelChief Executive Officer | SSale | −131.6K | $10.15 | −$1.34M | −100.0%0 after | 3 lots10b5-1 |
| Jun 6, 2025 (view filing) | Jun 4-6 | 2 days | Hallal DavidDirector | SSale | −114.7K | $10.15 | −$1.16M | −100.0%0 after | 3 lots10b5-1 |
| May 16, 2025 (view filing) | May 14-15 | 2 days | EcoR1 Capital, LLC10% Owner | PPurchase | +4.96M | $7.80 | +$38.7M | +86.5%10.7M after | 2 lots |
| May 15, 2025 (view filing)5:34 PM ET | May 13 | 2 days | Gadicke Ansbert and 3 othersOther: Former 10% Owner | SSale | −1.03M | $8.06 | −$8.32M | −23.0%3.45M after | |
| May 15, 2025 (view filing)5:33 PM ET | May 13 | 2 days | MPM Bioventures 2018, L.P. and 2 othersOther: Former 10% Owner | SSale | −630.2K | $8.06 | −$5.08M | −23.0%2.11M after | Duplicate filing |
| May 15, 2025 (view filing)5:32 PM ET | May 13 | 2 days | Evnin Luke and 8 othersOther: Former 10% Owner | SSale | −630.2K | $8.06 | −$5.08M | −23.0%2.11M after | |
| Nov 19, 2024 (view filing) | Nov 19 | Same day | Gall MatthewChief Financial Officer | PPurchase | +5.00K | $7.73 | +$38.6K | +8.3%65.4K after |
Top 10 13F holders, Q2 2025
The largest institutional positions in iTeos Therapeutics, Inc. at the end of Q2 2025; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 10,688,978 | $106.6M | 6.32% | +10,688,978 | New |
| BlackRock, Inc. | 4,574,537 | $45.6M | 0.00% | +65,290+1.4% | Added |
| Tang Capital Management LLC | 3,826,692 | $38.2M | 1.93% | +1,137,492+42.3% | Added |
| Vanguard Group Inc | 1,664,161 | $16.6M | 0.00% | −62,297−3.6% | Reduced |
| Dimensional Fund Advisors LP | 832,761 | $8.30M | 0.00% | −348,493−29.5% | Reduced |
| Boxer Capital Management, LLC | 825,000 | $8.23M | 4.14% | +825,000 | New |
| Geode Capital Management, LLC | 703,467 | $7.02M | 0.00% | +53,414+8.2% | Added |
| OrbiMed Advisors LLC | 700,000 | $6.98M | 0.18% | +700,000 | New |
| Marshall Wace, LLP | 611,649 | $6.10M | 0.01% | +492,091+411.6% | Added |
| Renaissance Technologies LLC | 602,100 | $6.00M | 0.01% | −43,500−6.7% | Reduced |